ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 212 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q4 2021. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $62,725,728 | -10.6% | 11,509,308 | +10.1% | 0.48% | +3.4% |
Q2 2023 | $70,144,675 | -13.7% | 10,453,752 | +13.6% | 0.46% | -17.0% |
Q1 2023 | $81,281,254 | +15.6% | 9,205,125 | +0.0% | 0.56% | -8.2% |
Q4 2022 | $70,297,512 | +5.7% | 9,201,245 | -1.4% | 0.61% | +31.5% |
Q3 2022 | $66,477,000 | -3.1% | 9,336,619 | +6.4% | 0.46% | +14.0% |
Q2 2022 | $68,605,000 | -35.9% | 8,773,018 | +13.8% | 0.41% | -9.2% |
Q1 2022 | $107,010,000 | -33.1% | 7,709,666 | +35.3% | 0.45% | -7.5% |
Q4 2021 | $159,882,000 | -3.1% | 5,697,868 | +17.3% | 0.48% | +22.0% |
Q3 2021 | $165,070,000 | -7.5% | 4,856,421 | +11.2% | 0.40% | +19.3% |
Q2 2021 | $178,435,000 | +27.6% | 4,366,977 | +25.7% | 0.33% | +19.4% |
Q1 2021 | $139,860,000 | +53.0% | 3,473,910 | +124.7% | 0.28% | +14.4% |
Q4 2020 | $91,397,000 | +112.4% | 1,545,703 | +74.7% | 0.24% | -4.7% |
Q3 2020 | $43,024,000 | +187.7% | 884,722 | +186.2% | 0.26% | +58.4% |
Q2 2020 | $14,956,000 | – | 309,138 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
Triatomic Management LP | 102,889 | $560,745 | 0.39% |